Novo’s Wegovy significantly reduces BMI in children aged six to 12
Novo reported Phase III STEP Young results for subcutaneous Wegovy (semaglutide) in children aged 6-<12 with obesity. At week 68, mean BMI fell 17.4% vs +2.2% with placebo. Novo said safety matched prior trials and no new concerns.
How this was made

The 30-second read
Why it matters
First disclosed Phase III efficacy and safety results for younger pediatric obesity provide a concrete catalyst for label-expansion expectations, with quantified BMI improvements and a proportion no longer meeting obesity criteria.
Market read
Quantified pediatric BMI reductions and consistent safety profile increase the probability-weighted upside for Wegovy’s addressable market, though approval timing remains unspecified.
What to watch
The article does not specify next regulatory steps, endpoints beyond BMI, or magnitude of adverse events, which could temper how quickly the market extrapolates to approval timing.
Background
Wegovy (semaglutide) is already approved in the US for children aged 12 and older; STEP Young evaluates once-weekly subcutaneous semaglutide plus lifestyle in children aged 6 to under 12.
Ticker impact
Novo’s STEP Young Phase III data show Wegovy cut BMI by 17.4% in 80% of children aged 6-12, supporting a potential label expansion.
Likely upward bias as investors price in higher future addressable market and potential FDA label expansion pathway.
The article reports first release of Phase III trial data with quantified BMI reductions and obesity reclassification, plus no unexpected safety issues, which are direct inputs to regulatory review expectations.
Market effects
Strengthens the GLP-1 obesity-treatment evidence base for pediatric use, potentially lifting sentiment across obesity and metabolic disease drug developers.
US-focused read-through via potential FDA label expansion for a drug already approved for ages 12+.
Could accelerate global pediatric obesity treatment adoption discussions and competitive trial expectations internationally.
Counterpoint
BMI reduction does not guarantee FDA approval; regulators may scrutinize durability, adherence, and long-term safety in younger children beyond the 68-week window.
Key entities
- companyNovo Nordisk
Sponsor of the STEP Young Phase III trial evaluating Wegovy in children aged 6 to under 12.
- drugWegovy (semaglutide)
Once-weekly GLP-1 therapy studied for pediatric obesity label expansion.
- clinical_trialSTEP Young trial (NCT05726227)
Phase III study whose first data release is reported here, presented at ObesityWeek 2026 and published in NEJM.
- regulatorFDA
US regulator whose approval would be required for any label expansion to children under 12.



